If you have been reading about BDNF and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
Selank is studied chiefly as an animal-model anxiolytic with proposed secondary effects on memory and immune signaling. Reported mechanisms include modulation of the GABA-A receptor complex, inhibition of enkephalin-degrading enzymes, and shifts in monoamine turnover within limbic structures. Some experiments describe increased expression of brain-derived neurotrophic factor in the hippocampus after repeated dosing. No single molecular target has been confirmed, and the peptide does not bind any receptor with the selectivity typical of a conventional small-molecule drug. Mechanism therefore remains a set of hypotheses rather than an established pathway.
Laboratory work relies on standard behavioral paradigms. Rodents are tested in the elevated plus maze, open field, and passive avoidance tasks, with outcomes compared against diazepam or vehicle controls. Intranasal dosing is used most often because it bypasses first-pass metabolism, though intraperitoneal and intravenous routes also appear in published protocols. Biochemical endpoints include tissue BDNF concentrations, cytokine levels, and monoamine metabolites. Human data are limited to small Russian trials reporting reduced anxiety scores; most were not prospectively registered, and few employed independent outcome assessment.
Measuring peptide exposure inside the brain is technically difficult. Selank is degraded rapidly in plasma, and assays must separate intact peptide from fragments, which favors targeted mass spectrometry over immunoassays alone. Reported half-lives are short, on the order of minutes, so effects observed hours later are attributed to downstream signaling rather than to the parent compound. Blood-brain barrier permeability is debated and rarely quantified directly. Gaps include absent dose-response characterization, inconsistent reporting of purity, and almost no pharmacokinetic data from human participants.
Animal studies have examined behaviour in tests of anxiety, memory retention and stress response, and several report changes in neurotrophic or neurotransmitter-related markers. The human evidence base is much smaller, consisting mainly of short trials conducted in Russia with limited reporting in English-language journals. Sample sizes are modest and outcome measures vary between studies, so the findings are best described as preliminary. Independent replication under modern trial standards has not been widely reported.
Outside its country of origin the compound is generally handled as a research chemical rather than an approved medicine. No regulatory approval from the United States Food and Drug Administration or the European Medicines Agency has been granted for human use. Identity and purity are normally checked by reverse-phase high-performance liquid chromatography, with mass spectrometry used to confirm the molecular mass. Lyophilised material is stored cold and desiccated, and repeated freeze-thaw cycles are avoided.
Published work on this peptide almost always uses intranasal delivery, with drops or a spray applied to the nasal mucosa. Some animal experiments have used subcutaneous or intraperitoneal injection, and a smaller number have compared routes directly. Oral administration is not a focus of the literature, because short peptides of this size are broken down by digestive enzymes and cross intestinal barriers poorly. How much of an intranasal dose reaches the bloodstream intact in humans remains an open question.
| Property | Value | Notes |
|---|---|---|
| Principal proposed target | GABA-A receptor complex | Hypothesis derived mainly from animal pharmacology |
| Common behavioral assay | Elevated plus maze | Rodent test for anxiety-like behavior |
| Reported molecular marker | Hippocampal BDNF expression | Measured by immunoassay or mRNA quantification |
| Typical dosing route | Intranasal | Chosen to reduce first-pass metabolism |
| Reported plasma half-life | Minutes | Based on limited peptide stability data |
Enzymatic stability motivates the extra three residues at the carboxyl end. Native tuftsin is cleaved quickly by circulating aminopeptidases and carboxypeptidases, which limits its duration of action and its usefulness as a tool compound. Extending the chain with proline-rich segments is a common design tactic because proline constrains the backbone and slows proteolysis. The same Pro-Gly-Pro motif appears in other Russian-developed peptides of the era. Whether the full seven-residue chain is required for activity, or whether it acts mainly as a prodrug releasing tuftsin, remains unresolved.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. Its four N-terminal residues reproduce tuftsin, a tetrapeptide fragment of the immunoglobulin heavy chain, while the C-terminal Pro-Gly-Pro extension is a synthetic addition. The peptide has a molecular mass near 752 daltons and carries a net positive charge at physiological pH because of the arginine and lysine side chains. Published indexes list it under the name Selank and the sequence abbreviation TKPRPGP. Solid-phase peptide synthesis is the standard production route for research quantities.
Development took place at the Institute of Molecular Genetics of the Russian Academy of Sciences, where a series of short peptides were designed in the 1980s and 1990s. Selank was selected from variants of tuftsin that showed resistance to plasma peptidases. Russian regulatory approval covers it as an anxiolytic agent given intranasally. Outside that market the compound is normally handled as a research chemical rather than a medicine, and no widely recognised international pharmacopoeial monograph exists. The name Selank is a coined trade designation rather than a systematic chemical name.
Regulatory status differs sharply by region. Selank holds a Russian marketing authorization, where it is supplied mainly as nasal drops, while authorities elsewhere have not approved it for medical use. Material sold internationally is therefore usually labeled as a research chemical rather than a medicine. Peer-reviewed publications come predominantly from Russian laboratories, and sample sizes are generally small. Whether the compound produces comparable effects under independent, well-controlled replication remains an open question that the broader literature has not settled.
Selank is a synthetic heptapeptide developed in Russia as a structural analogue of tuftsin, a naturally occurring immunomodulatory tetrapeptide. Its sequence, Thr-Lys-Pro-Arg-Pro-Gly-Pro, keeps the tuftsin core at the N-terminus and appends a Pro-Gly-Pro tail. Researchers at the Institute of Molecular Genetics in Moscow synthesized the compound during the 1990s while searching for peptides with combined anxiolytic and immunomodulatory activity. The added tail was intended to resist enzymatic cleavage and prolong the molecule's presence in circulation.
Hard and soft acid–base theory (HSAB). This is used mainly for qualitative purposes. Drago and Wayland proposed a two-parameter equation which predicts the standard enthalpy of formation of a very large number of adducts quite accurately. −ΔH⊖ (A − B) = EAEB + CACB. Values of the E and C parameters are available. Guttmann donor numbers: for bases the number is derived from the enthalpy of reaction of the base with antimony pentachloride in 1,2-Dichloroethane as solvent. For acids, an acceptor number is derived from the enthalpy of reaction of the acid with triphenylphosphine oxide.
== Synthesis == Covalent Organic Frameworks (COFs) have also been used to form cage architectures and in one such example Schiff base cyclization was used to form the macromolecular cage molecule. In this synthesis 1,3,5-triformylbenzene and (R,R)-(1,2)-diphenylethylenediamine undergo cycloimination in dichloromethane with trifluoroacetic acid as a catalyst to form a COF cage molecule. Macrocyclizations have also been employed to form peptoid based macromolecular cages, the specific methodology utilizes a one pot synthesis to form steroid-aryl hybrid cages using two- and three-fold Ugi type macrocyclization reactions. Dynamic covalent chemistry enables the formation of thermodynamically stable cage structures through reversible bond formation. The formation of imine bonds through the reaction between aldehyde and amine groups represents a fundamental example of this chemistry. This reversible nature allows for continuous bond breaking and reforming during synthesis, enabling error correction and driving the system toward the most thermodynamically stable products. The dynamic nature of these reactions is particularly crucial in cage synthesis for several reasons. The ability to self-correct defects during formation ensures the production of highly ordered structures with minimal imperfections. The formation of thermodynamically favored products leads to stable and well-defined cage architectures that can maintain their structural integrity under various conditions.
== Adverse effects == Adverse effects, especially with higher doses, include dizziness, drowsiness, fatigue, diarrhea, unusual dreams, trouble sleeping, depression, and vision problems such as blurred vision or dry eyes. β-blockers, including metoprolol, reduce salivary flow via inhibition of the direct sympathetic innervation of the salivary glands. Metoprolol may also cause the hands and feet to feel cold. Due to the high penetration across the blood–brain barrier, lipophilic beta blockers such as propranolol and metoprolol are more likely than other less lipophilic beta blockers to cause sleep disturbances such as insomnia, vivid dreams and nightmares. Patients should be cautious while driving or operating machinery due to its potential to cause decreased alertness. There may also be an impact on blood sugar levels, and it can potentially mask signs of low blood sugar. The safety of metoprolol during pregnancy is not fully established.
== Critical response == The Guardian editor Alex Macpherson praised the production: "Thr33 Ringz' humour is still superbly crass and mostly enjoyable, especially when allied with the skittering beats and post-funk bounce of Freeze." Jesal 'Jay Soul' Padania of RapReviews.com called this song nice enough. Eric Henderson wrote a positive review: "Freeze" might be another freeze-dried Chris Brown upper, but it boasts the cleanest production this side of Ne-Yo."
Sources: en.wikipedia.org
The slime of the hagfish is unique due to its volume and dilution. In these fish it serves as an anti-predator adaptation: when grabbed by a predator fish, the hagfish ejects copious amounts of slime into the predator's mouth, causing the predator to gag and flare its gills, releasing the hagfish and moving away.
== Education == Foyer attended Portsmouth Polytechnic (now the University of Portsmouth) from 1971–74, achieving a BSc with Class II, Division I Honours in Biology (CNAA). From 1974–77 she attended the Department of Biochemistry, King's College London, where she completed her PhD. During this time Foyer also attended a course on immunology at Chelsea College, London. In 1998 Foyer was elected a Fellow of the Institute of Biology.
=== Reign of Doomsday === Boodikka later appears at the remains of the destroyed planet New Krypton, where she encounters Batman and Supergirl. Boodikka explains that the Guardians had sent her on a mission to survey the ruins as a follow-up to the Green Lantern Corps' initial inspection of the planet. Suddenly, the heroes are attacked by Doomsday, who strikes Boodikka before she can react. Due to her injuries, Boodikka is unable to effectively wield her ring and is nearly captured by Doomsday before being rescued by Supergirl. With Starman and Saint Walker acting as a distraction, Batman and Supergirl take Boodikka to the JLA Watchtower. Doomsday follows the two aboard. As he's about to attack them, Cyborg Superman emerges from Boodikka's body. After Doomsday captures Supergirl and Cyborg Superman and flees the Watchtower, Starman states that Boodikka is healing herself in the Justice League's medical facility and should soon have enough energy to return to Oa. In War of the Green Lanterns, Boodikka and the Alpha Lanterns are killed by Alpha Lantern Varix and buried on Oa.
=== Fosfomycin === Several antimicrobial drugs have been tested for the effective treatment of CRE. Fosfomycin is an antimicrobial agent that acts to inhibit UDP-N-acetylglucosamine enolpyruvyl transferase (MurA) which catalyzes one of the early steps of bacterial cell wall synthesis, and is effective against gram-negative and -positive aerobic bacteria, such as CRE. A meta-analysis of 17 studies investigating the clinical effectiveness of fosfomycin in four multidrug-resistant strains of Enterobacteriaceae found 11 which reported that over 90% of bacterial isolates were susceptible to fosfomycin. The elevated level of antimicrobial activity by fosfomycin can be attributed to the fact that resistance to this antibiotic in Enterobacteriaceae is chromosomally encoded and not plasmid-mediated. This causes a decreased capacity for survival in the bacteria. Bacteria that are naturally resistant to fosfomycin are less robust and less pathogenic.
==== Tumor antigens ==== Tumor antigens are those antigens that are presented by MHC class I or MHC class II molecules on the surface of tumor cells. Antigens found only on such cells are called tumor-specific antigens (TSAs) and generally result from a tumor-specific mutation. More common are antigens that are presented by tumor cells and normal cells, called tumor-associated antigens (TAAs). Cytotoxic T lymphocytes that recognize these antigens may be able to destroy tumor cells. Tumor antigens can appear on the surface of the tumor in the form of, for example, a mutated receptor, in which case they are recognized by B cells. For human tumors without a viral etiology, novel peptides (neo-epitopes) are created by tumor-specific DNA alterations.
Sources: en.wikipedia.org
Intranasal administration predominates in both animal and human research because it avoids hepatic first-pass metabolism. Injectable and intraperitoneal routes appear in animal work mainly for comparison.
Behavioral endpoints include time spent in open arms of the elevated plus maze and avoidance latencies. Biochemical endpoints include BDNF concentration, cytokine levels, and monoamine metabolite ratios in brain tissue.
Most published studies are small, originate from a limited number of laboratories, and lack independent replication. Dose-response relationships, measured brain exposure, and long-term outcomes are not well characterized.
Most published work uses intranasal application, either as drops or as a nasal spray. Injection routes appear in a smaller set of animal experiments. Oral use is uncommon in the literature because peptide breakdown and poor absorption limit this route.